John Parkinson

A hospital reviewed both treatments in a real-world clinical setting to determine the effectiveness in preventing early and late recurrences.

The 2023 changes include vaccines for influenza, pneumococcal disease, measles, mumps, and rubella (MMR) and COVID-19.

The antiviral did not modify SARS–CoV-2 RNA clearance, and did not increase the risk of adverse events.

A phase 1 trial with the investigational vaccine, TNX-801, for the prevention of mpox and smallpox is expected to start in the second half of 2023.

A single-dose of peginterferon lambda demonstrated efficacy in a largely vaccinated cohort and the therapy accelerated clearance of the virus.

Chinese investigators said genome analysis suggests 2 existing Omicron sub-variants, BA52 and BF7, were among the most dominant variants in Beijing.

A prominent researcher offers some insights on this emerging fungal infection.

FDA says products have the potential to be contaminated with Listeria and were distributed along the east coast in several states.

Looking to appeal to the financial incentives of antibiotic development, a recent policy paper explores how lives can be saved and a return of investment (ROI) can be realized.

Can a similar approach that brought breakthrough therapies for cystic fibrosis bring about much needed change to antibiotic development?

The agency said it was revising the Emergency Use Authorizations (EUA) for Lagevrio and Paxlovid in order to protect public health.

A specific brand, EzriCare Artificial Tears, has been associated with multidrug resistant (MDR) Pseudomonas aeruginosa. In addition, FDA has sent a letter to companies making claims of prevention and treatment for mpox.

The declaration set for May is a wind-down to allow health care and patients the time needed to adjust for the emergency to be over.

The designation was based on positive top line data from the ConquerRSV phase 3 efficacy trial.

The investigational therapy developed by Entasis is indicated for treatment of Acinetobacter baumannii.

In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.

The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.

In the CDC’s latest Morbidity and Mortality Weekly Report, investigators reported the Moderna and Pfizer-BioNTech updated vaccines helped prevent acute infection from the latest Omicron mutations.

The new guidance looks at preexposure and postexposure prophylaxis as well as treatment for COVID-19.

A new study demonstrated continuous neutralization after 3 doses.

In this week’s meeting, FDA is expected to ask their advisory committee to consider changes to simplify the vaccination schedule and look at delivering it annually, much like an influenza vaccine.

A Chinese epidemiologist made this claim this weekend as the country gathers for its Lunar New Year celebrations.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Although vaccine rates overall remain high, a new report shows a reduction 2 years in a row, leaving thousands of children not vaccinated against vaccine-preventable viruses.

A retrospective study showed that exercise was found to have a protective association to adverse COVID-19 outcomes.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

With limited health care infrastructure and large swaths of remote areas, developing countries face difficulties in medical management with these viruses and parasitic diseases.

This act designed to allow pharmacists and technicians the ability to administer certain vaccines without a prescriber order will lapse next year. A new report looks at vaccination trends in the US and how pharmacists are playing a vital role in administering vaccines.

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.

This live-attenuated investigational vaccine was developed by Codagenix, which uses its codon de-optimization platform for its candidates.